6.36
+1.71(+36.77%)
Currency In USD
| Previous Close | 4.65 |
| Open | 4.56 |
| Day High | 7.09 |
| Day Low | 4.34 |
| 52-Week High | 48.91 |
| 52-Week Low | 2.2 |
| Volume | 7.6M |
| Average Volume | 3.41M |
| Market Cap | 299.49M |
| PE | -37.41 |
| EPS | -0.17 |
| Moving Average 50 Days | 6.56 |
| Moving Average 200 Days | 6.56 |
| Change | 1.71 |
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
GlobeNewswire Inc.
Feb 27, 2026 1:30 PM GMT
PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), joins the global rare
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
GlobeNewswire Inc.
Feb 17, 2026 1:30 PM GMT
PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it ha
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil)PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutic